Differential risk of Alzheimer's disease in MCI subjects with elevated Abeta

J Neurol Sci. 2024 Dec 15:467:123319. doi: 10.1016/j.jns.2024.123319. Epub 2024 Nov 23.

Abstract

Backgrounds: People with elevated beta amyloid have different risk and progress speed to Alzheimer's disease.

Purpose: The research is to validate the risk classification of AD developed in the Shanghai mild cognitive impairment (MCI) cohort study using ADNI data.

Methods: The risk classification of AD in MCI was based on several optimal cut-off points of a novel parameter Cog_Vol.

Results: In total, 843 subjects with MCI were included, of whom 220 had elevated PET beta amyloid. 273 (32.3 %) and 70 (31.8 %) progressed to AD in all subjects and in those with elevated PET beta amyloid, respectively. The risk of AD in subjects whose Cog_Vol >340 was very low, while the risk for those with Cog_Vol less than 101 indicated a super high within 4 years of follow-up.

Discussion: Risk classification using Cog_Vol at an optimal value was able to detect subjects among those with PET-amyloid-elevated MCI were at greater risk of developing AD and were unlikely to develop AD within 4 years of follow-up.

Keywords: Alzheimer's disease; Mild cognitive impariment; PET beta amyloid; Risk assessment.

MeSH terms

  • Aged
  • Aged, 80 and over
  • Alzheimer Disease* / diagnosis
  • Alzheimer Disease* / epidemiology
  • Amyloid beta-Peptides* / metabolism
  • China / epidemiology
  • Cognitive Dysfunction* / diagnosis
  • Cognitive Dysfunction* / epidemiology
  • Cohort Studies
  • Disease Progression
  • Female
  • Humans
  • Male
  • Middle Aged
  • Positron-Emission Tomography*

Substances

  • Amyloid beta-Peptides